Back to top
more

Aduro Biotech, Inc. (ADRO)

(Delayed Data from NSDQ)

$4.26 USD

4.26
328,546

+0.11 (2.65%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Anthera's Blisibimod Positive in Phase II Extension Study

by Zacks Equity Research

Anthera's (ANTH) blisibimod passes test in an extended phase II study to prove efficacy for IgA nephropathy treatment. The study also shows a trend toward preservation of renal function.

    Roche's Gazyva Gets Priority Review for Follicular Lymphoma

    by Zacks Equity Research

    Roche Holding AG (RHHBY) announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review to leukaemia drug Gazyva.

      J&J's (JNJ) Xarelto/Aspirin Regimen Positive in Phase III

      by Zacks Equity Research

      J&J's (JNJ) blood thinner Xarelto shows a significant risk reduction in major cardiovascular events in patients with stable coronary and peripheral artery disease.

        Minerva-J&J's Amendment of MIN-202 Contract Wins EU Approval

        by Zacks Equity Research

        The EU approves of Minerva's (NERV) amendment of MIN-202 license agreement with Janssen. Per the deal, Minerva will receive an upfront payment from Janssen.

          Novartis Announces Positive Data on Cardiovascular Drug

          by Zacks Equity Research

          Novartis AG (NVS) announced positive primary data on pipeline candidate canakinumab (ACZ885).

            Kamada (KMDA) Gets FDA Approval for Rabies Vaccine

            by Zacks Equity Research

            Kamada Ltd. (KMDA) and partner Kedrion Biopharma and announced that FDA has approved Kedrab [rabies immune globulin (Human)] for post-exposure prophylaxis against rabies infection.

              Will Endo (ENDP) Continue to Disappoint Investors in 2017?

              by Zacks Equity Research

              Endo (ENDP) a global specialty pharmaceutical company focused on branded and generic pharmaceuticals, is under significant pressure due to intensifying consortium pricing pressures and additional competitive entrants and product discontinuations.

                Ultragenyx Files BLA to FDA for Hypophosphatemia Candidate

                by Zacks Equity Research

                Ultragenyx (RARE) forwards a BLA to the FDA for burosumab with a view to treat patients with X-linked hypophosphatemia (XLH). The decision on acceptance will be known within a couple of months.

                  Novartis (NVS) Receives EC Approval for Breast Cancer Drug

                  by Zacks Equity Research

                  Novartis AG (NVS) obtained approval for its breast cancer drug Kisqali in Europe.

                    Ultragenyx (RARE) Posts Disappointing Phase III Ace-ER Data

                    by Zacks Equity Research

                    Ultragenyx (RARE) plans to discontinue further clinical development of Ace-ER after posting discouraging data from a phase III study that evaluated the candidate on patients with GNE Myopathy.

                      Perrigo's (PRGO) OTC Version of Nexium Secures FDA Approval

                      by Zacks Equity Research

                      Perrigo (PRGO) gains an FDA consent for the OTC version of AstraZeneca's Nexium post the ongoing patent lawsuit settlement through an agreement.

                        BioLineRx Moves a Regulatory Submission for BL-8040 Trial

                        by Zacks Equity Research

                        BioLineRx (BLRX) forwards a regulatory submission to begin a phase III study to evaluate BL-8040 in combination with G-CSF for treatment of multiple myeloma.

                          Alkermes Initiates Rolling Submission of Depression Drug

                          by Zacks Equity Research

                          Alkermes (ALKS) initiated the rolling submission of a New Drug Application (NDA) to the FDA for pipeline candidate ALKS 5461 for major depressive disorder.

                            Alexion's (ALXN) Soliris' Label Expansion Approved in Europe

                            by Zacks Equity Research

                            Alexion Pharmaceuticals (ALXN) announced that the European Commission (EC) approved a label expansion of lead drug Soliris which should further boost sales.

                              Jazz Pharmaceuticals Arm Announces $500M Senior Notes Offer

                              by Zacks Equity Research

                              Jazz Pharmaceuticals (JAZZ) announces private offering of exchangeable senior notes to qualified institutional buyers to raise proceeds and repay debt.

                                Mallinckrodt (MNK) Looks Strong on Acthar, Generics Weak

                                by Zacks Equity Research

                                Mallinckrodt undertaking strategic acquisitions and divestitures to evolve as a high-performing specialty pharmaceutical company.

                                  Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern

                                  by Zacks Equity Research

                                  Geron Corporation's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.

                                    Novo Nordisk (NVO) Beats on Q2 Earnings, Revenues Miss

                                    by Zacks Equity Research

                                    Novo Nordisk A/S (NVO) beat earnings estimates but missed revenue estimates in Q2. Robust performance for Victoza and Tresiba will drive growth.

                                      Catalyst (CPRX) Posts Narrower than Expected Loss in Q2

                                      by Zacks Equity Research

                                      Catalyst Pharmaceuticals, Inc. (CPRX) reported narrower than expected loss in Q2 and is focused on the development of its pipeline candidate Firdapse.

                                        Perrigo (PRGO) Q2 Earnings & Sales Top, 2017 View Raised

                                        by Zacks Equity Research

                                        Perrigo (PRGO) posts better-than-expected results with revenue beating estimates. The company also ups its earnings outlook, courtesy a continued positive execution across all business segments.

                                          Merrimack (MACK) Q2 Loss Wider than Expected, Stock Falls

                                          by Zacks Equity Research

                                          Merrimack Pharmaceuticals (MACK) reported wider-than-expected loss in the second quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.

                                            Valeant (VRX) Beats Q2 Earnings, Sales in Line, Trims View

                                            by Zacks Equity Research

                                            Valeant's (VRX) second-quarter results were encouraging but the company trimmed its guidance due to recent divestitures.

                                              Jazz Pharma (JAZZ) Q2 Earnings & Revenues Miss, View Intact

                                              by Zacks Equity Research

                                              Jazz Pharma's (JAZZ) earnings and revenues miss estimates. However, the top line rises year over year owing to higher sales of the company's marketed drug, Xyrem.

                                                Orexigen (OREX) Q2 Loss Narrows, Contrave Sales Impress

                                                by Zacks Equity Research

                                                Orexigen Therapeutics (OREX) reported adjusted loss of $1.82 per share in the second quarter of 2017, which was narrower than the Zacks Consensus Estimate. The company is focused on increasing the reach of Contrave.

                                                  Agios (AGIO) Q2 Loss Wider than Expected, Revenues Up Y/Y

                                                  by Zacks Equity Research

                                                  Agios (AGIO) reports wider-than-expected loss with revenues marginally lagging estimates. However, the top line improves year over year, thanks to reimbursement received from Celgene.